Clinical trials: Heart Disease
Tachyarrhythmia
Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study
Following product approval, further confirmation of the MR Conditional Tachyarrhythmia Therapy Systems sensing and detection performance post MRI exposure will be obtained by actively monitoring de-identified device data obtained…
- Trial name
- NCT02849769
- Testing
- Implant of an MR-conditional Tachy device system
- Volunteers
- 10,979 people
- Sponsor
- Medtronic
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Sarcoidosis, Cardiac
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
- Trial name
- RESOLVE-Heart (NCT05351554)
- Testing
- Namilumab
- Where
- 12 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Kinevant Sciences GmbH
Cardiovascular Disease, de Novo Coronary Lesions
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical…
- Trial name
- ARRIVE 2 (NCT00569751)
- Testing
- TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
- Where
- 53 sites in United States
- Volunteers
- 5,016 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Paroxysmal Atrial Fibrillation
FIRE AND ICE Re-Ablations (Retrospective Data Collection)
Retrospective data collection on re-ablations performed within the FIRE AND ICE Trial.
- Trial name
- Re-Do (NCT03314753)
- Testing
- No interventions - retrospective data collection
- Where
- 13 sites in Czechia, France and 4 more
- Volunteers
- 89 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Pulmonary Hypertension
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
This is an open-label, multicenter study evaluating the dose, effect, safety and tolerability of intravenous PDNO infusion given to patients undergoing cardiopulmonary bypass (CPB) surgery with post-operative acute pulmonary…
- Trial name
- NCT05699486
- Testing
- PDNO
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Attgeno AB
Coronary Artery Disease
A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
Title: A randomized, double-blind, multi-centered, placebo-controlled trial to examine effects of of Heart-protecting Musk Pill on clinical outcomes in patients with chronic stable coronary artery disease Objective: To examine…
- Trial name
- NCT01897805
- Testing
- Heart-protecting Musk Pill
- Where
- 98 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Mitral Regurgitation, Mitral Insufficiency
AltaValve Early Feasibility Study Protocol
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for…
- Conditions
- Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
- Trial name
- NCT03997305
- Testing
- AltaValve
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- 4C Medical Technologies, Inc.
Heart Failure
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure.
- Trial name
- NCT01751022
- Testing
- Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
- Where
- 121 sites in United States, Australia and 25 more
- Volunteers
- 1,202 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Chronic Disease
Digital Literacy of Chronic Heart Failure Patients
A retrospective cohort study was conducted using a web application (Satelia®Cardio by NP Medical) for the management of chronic heart failure.
- Trial name
- NCT07626853
- Where
- France
- Volunteers
- 26,000 people
- Sponsor
- Satelia
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Heart Failure
Data Collection Study of Wedge Pressure Data in Patients With CRT-D Devices
zWedge is a clinical feasibility IDE study. The objective is to characterize the relationship between intra-thoracic impedance measurements obtained from a CRT-D device and pulmonary capillary wedge pressure (PCWP) measured via a…
- Trial name
- zWedge (NCT00811551)
- Testing
- CRT-D (Intra-thoracic Impedance Monitoring)
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Abbott Medical Devices
Mitral Valve Insufficiency
MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States
The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).
- Trial name
- MAVERIC US (NCT03311295)
- Testing
- ARTO System
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mvrx, Inc.
Coronary Artery Disease, Drug Eluting Balloon
Stents Versus PAclitaxel Coated Balloons for Revascularization of CompleX and Small Coronary Vessels (SPARX) Trial
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two…
- Conditions
- Coronary Artery Disease, Drug Eluting Balloon, Drug Eluting Stent
- Trial name
- SPARX RCT (NCT07397845)
- Testing
- Protégé and Protégé NC, Agent, Drug Eluting Stent
- Where
- Switzerland
- Volunteers
- 1,380 people
- Sponsor
- Translumina GmbH
Chest Pain, Coronary Artery Disease
A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (or ASGES) in Primary Care Settings
The PRESET Registry--A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (Age/Sex/Gene Expression score - ASGES) in Real World Clinical Care Settings (PRESET)--was designed as an observational…
- Conditions
- Chest Pain, Coronary Artery Disease, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- PRESET (NCT01677156)
- Testing
- CORUS CAD (ASGES)
- Where
- 13 sites in United States
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- CardioDx
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Arrhythmias
Identification for the Treatment of Complex Arrhythmias
The primary purpose of this trial is to demonstrate that the utilization of CartoFinder™ 4D Local Activation Time (LAT) Algorithm may help identify and improve the outcome for the treatment of complex arrhythmias.
- Trial name
- NCT02565069
- Testing
- CartoFinder™ Device with CARTO® 3 System V5 Navigation
- Where
- 4 sites in Belgium, Czechia
- Volunteers
- 70 people
- Sponsor
- Biosense Webster, Inc.
Chronic Heart Failure
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.
- Trial name
- NCT00272805
- Testing
- carvedilol
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- Cardiovascular Clinical Sciences Inc
Atrial Fibrillation, Hypertension
Validation Study of an Advanced Blood Pressure Monitor
The proposed clinical study aims to validate the effectiveness of the WPM04 blood pressure monitor developed by Withings as a diagnostic tool for cardiovascular disorders.
- Conditions
- Atrial Fibrillation, Hypertension, Valvular Heart Disease
- Trial name
- TALISMAN (NCT04030494)
- Testing
- BP measurement, AF detection, VHD detection
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Withings
Congestive Heart Failure
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral…
- Trial name
- NCT03772041
- Testing
- OPC-61815, Tolvaptan Tab 15 MG
- Where
- Japan
- Volunteers
- 294 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.